UPMC Hillman Cancer Center | Strategic Alliance Partners

November 27, 2019

Robert L. Ferris, MD, PhD, discusses combining STING agonists with checkpoint inhibitors in head and neck cancer.

November 05, 2019

Antoinette Wozniak, MD, FACP, FASCO, discusses sequencing with immunotherapy and chemoradiation in select patients with stage III lung cancer.

October 30, 2019

Timothy F. Burns, MD, PhD, discusses methods of identifying genetic alterations in lung cancer.

October 28, 2019

Liza C. Villaruz, MD, discusses the data with immunotherapy in squamous non–small cell lung cancer.

October 24, 2019

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the University of Pittsburgh Medical Center faculty.

October 24, 2019

Timothy F. Burns, MD, PhD, discusses the frontline standards of care in EGFR-, ALK-, and ROS1-positive non–small cell lung cancer, optimal sequencing strategies, and the nuances of tissue- and plasma-based sequencing.

October 22, 2019

Antoinette Wozniak, MD, FACP, FASCO, discusses the promise of immunotherapy in lung cancer and shared ongoing research efforts further exploring this approach.

October 19, 2019

Bernard Fisher, MD, a world-renowned physician/scientist and the chair of the National Surgical Adjuvant Breast and Bowel Project for more than 27 years, has died at the age of 101.

October 08, 2019

Leisha A. Emens, MD, PhD, discusses the rationale behind the KATE2 study and the results that may signal clinical significance.

August 29, 2019

Robert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses the activity of venetoclax (Venclexta) in acute myeloid leukemia (AML).

August 22, 2019

Alexander Olawaiye, MD, discusses the trials that led to the expanded approvals of PARP inhibitors as maintenance therapy in women with platinum-sensitive ovarian cancer.

August 20, 2019

James M. Rossetti, DO, hematologist, UPMC Hillman Cancer Center, discusses risk stratification in myeloproliferative neoplasms (MPNs).

August 13, 2019

Sarah E. Taylor, MD, discusses the role of somatic and germline testing for patients with ovarian cancer and their family members to create more personalized treatment and prevent disease.

December 18, 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses cost mitigation practices that can be implemented before more biosimilars reach the United States market.

December 16, 2018

Rachel C. Jankowitz, MD, discusses the range of risk associated with HR-positive, HER2-negative breast cancer and the importance of communicating with patients about associated adverse events.

December 11, 2018

Shannon L. Puhalla, MD, discusses some of the advances being made in systemic treatment for patients with brain metastases from breast cancer.

December 11, 2018

Terry L. Evans, MD, discusses the impact of CDK4/6 inhibitors in the metastatic breast cancer space and challenges that still need to be addressed.

December 05, 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, addresses biosimilar skepticism.

December 04, 2018

Adam M. Brufsky, MD, PhD, associate director, Clinical Investigation, University of Pittsburgh, discusses genomic assays for breast cancer.

November 29, 2018

Pembrolizumab has emerged as a reliable frontline treatment option for patients with metastatic non–small cell lung cancer, but thoracic oncologists need to be aware of potentially severe immune-related adverse events.